Key Insights
The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is experiencing robust growth, projected to reach $3.18 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 16.73% from 2025 to 2033. This expansion is fueled by several key factors. The increasing prevalence of chronic diseases like oncology, cardiovascular diseases, and neurological disorders is driving demand for innovative cell and gene therapies. Simultaneously, advancements in gene editing technologies like CRISPR-Cas9 and viral vector production are significantly enhancing the efficacy and safety profiles of these therapies, further stimulating market growth. The rising number of clinical trials and approvals for cell and gene therapies are contributing to the expansion of this market, creating opportunities for CDMOs to provide essential development and manufacturing services. Furthermore, the outsourcing trend among pharmaceutical and biotechnology companies is accelerating due to the complex and specialized nature of cell and gene therapy manufacturing, requiring significant investments in infrastructure and expertise. This trend fuels the growth of established and emerging CDMOs that offer comprehensive services, including process development, analytical testing, and GMP manufacturing.
Geographic distribution shows a concentration of market share in North America, driven by robust regulatory frameworks, substantial R&D investments, and the presence of major market players. However, significant growth potential exists in the Asia Pacific region, fueled by increasing healthcare spending, growing biopharmaceutical industry, and government initiatives promoting cell and gene therapy research and development. Competition within the CDMO market is intense, with large multinational companies and specialized smaller firms vying for market share. The competitive landscape is characterized by strategic collaborations, mergers, and acquisitions, as companies seek to broaden their service offerings and expand their geographic reach. Future growth is expected to be shaped by technological advancements, regulatory approvals, pricing strategies, and the ongoing development of novel cell and gene therapies targeting a wider range of diseases.

Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market: A Comprehensive Report (2019-2033)
This detailed report provides a comprehensive analysis of the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market, covering the period from 2019 to 2033. It offers in-depth insights into market dynamics, competitive landscape, technological advancements, and future growth prospects. The report is essential for industry stakeholders, investors, and researchers seeking a thorough understanding of this rapidly evolving sector. The global market is projected to reach xx Million by 2033, exhibiting a CAGR of xx% during the forecast period (2025-2033).
Cell And Gene Therapy Contract Development And Manufacturing Organization Market Market Structure & Competitive Dynamics
The Cell and Gene Therapy CDMO market is characterized by a moderately concentrated structure with a few large players holding significant market share. However, the presence of numerous smaller, specialized CDMOs fosters a dynamic and innovative ecosystem. The market's competitive intensity is driven by factors such as technological advancements, regulatory changes, and intense competition for contracts. Market share is largely dictated by capacity, expertise in specific therapeutic areas (e.g., viral vector production, cell processing), and regulatory compliance.
Several key metrics drive competitive advantage:
- Technological Expertise: Advanced capabilities in viral vector production (AAV, lentivirus), cell expansion, and process analytical technology (PAT) are critical differentiators.
- Regulatory Compliance: Stringent adherence to GMP (Good Manufacturing Practice) guidelines is paramount for securing contracts.
- Capacity & Scalability: The ability to handle large-scale manufacturing is crucial for meeting growing demand.
- Service Offering Breadth: Comprehensive service packages encompassing process development, analytical testing, and manufacturing are highly desirable.
Mergers and acquisitions (M&A) activity is significant, reflecting the strategic consolidation within the industry. Notable deals in recent years have involved companies seeking to expand their therapeutic areas of expertise, manufacturing capacity, or geographical reach. The total value of M&A transactions in the past five years has exceeded xx Million. Examples include (though specific deal values are not publicly available for all transactions and are therefore omitted): large CDMOs acquiring smaller specialized companies to enhance their technology portfolios.
Cell And Gene Therapy Contract Development And Manufacturing Organization Market Industry Trends & Insights
The Cell and Gene Therapy CDMO market is experiencing robust growth, driven primarily by advancements in gene editing technologies (like CRISPR-Cas9), an expanding pipeline of cell and gene therapies, and increasing investments in research and development. The market is characterized by several key trends:
- Technological Disruption: Continuous innovation in gene editing, viral vector technology, and cell processing methods is driving efficiency gains and enabling the development of novel therapies. This trend is further fueled by the development of closed systems and automation, enhancing safety and reducing manufacturing costs.
- Growing Demand for Cell & Gene Therapies: The rising prevalence of chronic diseases like cancer and genetic disorders, coupled with the demonstrated efficacy of cell and gene therapies, is boosting demand for CDMO services. The market is expected to witness continued growth driven by the increasing number of clinical trials and approvals of new cell and gene therapies.
- Increased Regulatory Scrutiny: The regulatory landscape for cell and gene therapies is evolving, requiring CDMOs to adhere to rigorous standards for quality and safety. This is creating a need for specialized expertise and investment in compliance.
- Shift towards Integrated Solutions: CDMOs are increasingly adopting an integrated approach, offering a comprehensive suite of services covering the entire drug development lifecycle, from early-stage process development to commercial manufacturing.
- Geographic Expansion: The market is expanding globally, with regions like Asia-Pacific witnessing significant growth, driven by increasing investments in biotechnology and rising healthcare expenditure.

Dominant Markets & Segments in Cell And Gene Therapy Contract Development And Manufacturing Organization Market
The North American market currently holds the largest market share in the Cell and Gene Therapy CDMO sector, driven by robust funding, established regulatory frameworks, and a strong presence of both large and specialized CDMOs. However, regions like Europe and Asia-Pacific are experiencing rapid growth, fueled by increasing investments in research and development, growing healthcare expenditure, and supportive government initiatives.
- Dominant Indication: Oncology is the dominant therapeutic area for cell and gene therapy development, driving a significant portion of the CDMO market. The high prevalence of various types of cancer and the potential of cell and gene therapies to offer novel treatment modalities contribute to this dominance.
- Dominant Product Type: Viral vector-based gene therapy currently commands a substantial share of the market, reflecting the dominance of AAV and lentiviral vectors as delivery systems. However, cell therapy is growing rapidly, and the emergence of innovative approaches is expected to contribute to significant market share expansion in the coming years.
- Dominant Stage: The clinical stage currently dominates, reflecting the growing number of cell and gene therapies progressing through clinical trials. However, the pre-clinical stage is also showing promising growth with an increase in the number of therapies entering pre-clinical evaluation.
Key drivers for regional dominance include:
- North America: Strong R&D investment, established regulatory frameworks, and a high concentration of biopharmaceutical companies.
- Europe: Growing R&D funding, supportive government policies, and a well-developed healthcare infrastructure.
- Asia-Pacific: Rising healthcare expenditure, an expanding biopharmaceutical industry, and increasing government support for the biotechnology sector.
Cell And Gene Therapy Contract Development And Manufacturing Organization Market Product Innovations
Recent product innovations in the Cell and Gene Therapy CDMO space focus on enhancing manufacturing efficiency, scalability, and product quality. Advances in viral vector production, including the use of novel cell lines and process improvements, are crucial. Automation and closed-system technologies are being widely adopted to mitigate risks associated with contamination and variability. These innovations are directly impacting market fit by lowering manufacturing costs and improving product consistency, thus attracting increased investment and accelerating clinical development.
Report Segmentation & Scope
This report segments the Cell and Gene Therapy CDMO market based on:
Indication: Oncology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases, Neurological Diseases, Others. Growth is expected to be strongest in Oncology and Genetic Diseases, driven by the large unmet medical needs and significant therapeutic potential.
Product: Cell Therapy, Gene Therapy, Other Therapies. Gene therapy, primarily via viral vector delivery, presently holds a larger market share. However, cell therapy is projected to witness rapid growth in the coming years.
Stage: Pre-clinical, Clinical, Commercial. The clinical stage currently dominates, but the commercial stage is expected to gain significant traction as more therapies receive regulatory approval. Each stage exhibits unique characteristics regarding the CDMO services required and the associated pricing and competitive dynamics.
Key Drivers of Cell And Gene Therapy Contract Development And Manufacturing Organization Market Growth
Several key factors are driving the growth of the Cell and Gene Therapy CDMO market:
Technological Advancements: Continuous innovation in gene editing tools, viral vector technology, and cell processing methodologies is accelerating development timelines and improving the efficacy of therapies. Examples include the development of high-throughput screening methods and closed-system manufacturing technologies.
Rising Prevalence of Chronic Diseases: The increasing incidence of conditions such as cancer, genetic disorders, and cardiovascular diseases is creating a surge in demand for novel therapeutic approaches.
Favorable Regulatory Landscape: The increasing regulatory clarity and supportive policies in key markets are facilitating the launch of new therapies.
Challenges in the Cell And Gene Therapy Contract Development And Manufacturing Organization Market Sector
Despite significant growth potential, the Cell and Gene Therapy CDMO market faces several challenges:
High Manufacturing Costs: The production of cell and gene therapies is inherently complex and costly, posing a significant barrier to market entry for smaller companies. This creates a challenge for affordability of therapies for many patients.
Regulatory Hurdles: The stringent regulatory requirements and complexities associated with gaining approvals for cell and gene therapies can slow down the development and commercialization of products. Increased regulatory scrutiny is slowing the process.
Supply Chain Constraints: The availability of critical raw materials and specialized equipment can pose challenges for CDMOs, potentially leading to production bottlenecks. The global supply chain issues impact both availability of reagents and delivery of goods for manufacture.
Leading Players in the Cell And Gene Therapy Contract Development And Manufacturing Organization Market Market
- The Discovery Labs
- Patheon Inc
- Wuxi Advanced Therapies
- Lonza Group
- Almac Group
- Charles River Laboratories International Inc
- Pfizer CentreOne
- PCI Pharma Services
- BIOCENTRIQ
- Catalent Inc
- FUJIFILM Diosynth Biotechnologies
- Recipharm AB
Key Developments in Cell And Gene Therapy Contract Development And Manufacturing Organization Market Sector
March 2023: Porton Advanced Solutions Ltd. partnered with DanausGT Biotechnology Co., Ltd., creating a comprehensive gene and cell therapy service provider, accelerating development through combined expertise and CRISPR/AAV technology.
March 2023: Charles River Laboratories Inc. launched a Helper Plasmid to streamline AAV vector manufacturing, enhancing efficiency and simplifying production.
Strategic Cell And Gene Therapy Contract Development And Manufacturing Organization Market Market Outlook
The Cell and Gene Therapy CDMO market exhibits significant growth potential, driven by continuous technological innovation, expanding therapeutic applications, and increasing investments in R&D. Strategic opportunities lie in expanding capacity, developing specialized expertise in emerging therapeutic modalities, and adopting automation and process optimization technologies. The market is expected to witness considerable expansion, fueled by the increasing number of clinical trials and approvals of new therapies. Companies adopting strategic partnerships and investments in advanced technologies will be best positioned to capitalize on future market growth.
Cell And Gene Therapy Contract Development And Manufacturing Organization Market Segmentation
-
1. Product
-
1.1. Cell Therapy
- 1.1.1. Stem-cell Based
- 1.1.2. Non Stem-cell Based
- 1.1.3. Other Therapies
-
1.2. Gene Therapy
- 1.2.1. Viral Vectors
- 1.2.2. Non-viral Vectors
-
1.1. Cell Therapy
-
2. Stage
- 2.1. Pre-clinical
- 2.2. Clinical
- 2.3. Commercial
-
3. Indication
- 3.1. Oncology
- 3.2. Cardiovascular Diseases
- 3.3. Infectious Diseases
- 3.4. Genetic Diseases
- 3.5. Neurological Diseases
- 3.6. Others Indications
Cell And Gene Therapy Contract Development And Manufacturing Organization Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. United Kingdom
- 2.2. Germany
- 2.3. France
- 2.4. Spain
- 2.5. Italy
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. India
- 3.2. Japan
- 3.3. China
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of the Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America

Cell And Gene Therapy Contract Development And Manufacturing Organization Market REPORT HIGHLIGHTS
Aspects | Details |
---|---|
Study Period | 2019-2033 |
Base Year | 2024 |
Estimated Year | 2025 |
Forecast Period | 2025-2033 |
Historical Period | 2019-2024 |
Growth Rate | CAGR of 16.73% from 2019-2033 |
Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rise In Preclinical and Clinical Activities Around Cell and Gene Therapies; Growing Burden of Genetic Diseases and Cancer; Increasing Research and Development Investment for Cell and Gene Therapy
- 3.3. Market Restrains
- 3.3.1. Limitations in Analytical Methods for Large-scale AAV Biomanufacturing; Complex Manufacturing Process and Regulatory Challenges
- 3.4. Market Trends
- 3.4.1. Neurological Disorders Segment is Expected to Hold a Significant Share Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Product
- 5.1.1. Cell Therapy
- 5.1.1.1. Stem-cell Based
- 5.1.1.2. Non Stem-cell Based
- 5.1.1.3. Other Therapies
- 5.1.2. Gene Therapy
- 5.1.2.1. Viral Vectors
- 5.1.2.2. Non-viral Vectors
- 5.1.1. Cell Therapy
- 5.2. Market Analysis, Insights and Forecast - by Stage
- 5.2.1. Pre-clinical
- 5.2.2. Clinical
- 5.2.3. Commercial
- 5.3. Market Analysis, Insights and Forecast - by Indication
- 5.3.1. Oncology
- 5.3.2. Cardiovascular Diseases
- 5.3.3. Infectious Diseases
- 5.3.4. Genetic Diseases
- 5.3.5. Neurological Diseases
- 5.3.6. Others Indications
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Middle East and Africa
- 5.4.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Product
- 6. North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Product
- 6.1.1. Cell Therapy
- 6.1.1.1. Stem-cell Based
- 6.1.1.2. Non Stem-cell Based
- 6.1.1.3. Other Therapies
- 6.1.2. Gene Therapy
- 6.1.2.1. Viral Vectors
- 6.1.2.2. Non-viral Vectors
- 6.1.1. Cell Therapy
- 6.2. Market Analysis, Insights and Forecast - by Stage
- 6.2.1. Pre-clinical
- 6.2.2. Clinical
- 6.2.3. Commercial
- 6.3. Market Analysis, Insights and Forecast - by Indication
- 6.3.1. Oncology
- 6.3.2. Cardiovascular Diseases
- 6.3.3. Infectious Diseases
- 6.3.4. Genetic Diseases
- 6.3.5. Neurological Diseases
- 6.3.6. Others Indications
- 6.1. Market Analysis, Insights and Forecast - by Product
- 7. Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Product
- 7.1.1. Cell Therapy
- 7.1.1.1. Stem-cell Based
- 7.1.1.2. Non Stem-cell Based
- 7.1.1.3. Other Therapies
- 7.1.2. Gene Therapy
- 7.1.2.1. Viral Vectors
- 7.1.2.2. Non-viral Vectors
- 7.1.1. Cell Therapy
- 7.2. Market Analysis, Insights and Forecast - by Stage
- 7.2.1. Pre-clinical
- 7.2.2. Clinical
- 7.2.3. Commercial
- 7.3. Market Analysis, Insights and Forecast - by Indication
- 7.3.1. Oncology
- 7.3.2. Cardiovascular Diseases
- 7.3.3. Infectious Diseases
- 7.3.4. Genetic Diseases
- 7.3.5. Neurological Diseases
- 7.3.6. Others Indications
- 7.1. Market Analysis, Insights and Forecast - by Product
- 8. Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Product
- 8.1.1. Cell Therapy
- 8.1.1.1. Stem-cell Based
- 8.1.1.2. Non Stem-cell Based
- 8.1.1.3. Other Therapies
- 8.1.2. Gene Therapy
- 8.1.2.1. Viral Vectors
- 8.1.2.2. Non-viral Vectors
- 8.1.1. Cell Therapy
- 8.2. Market Analysis, Insights and Forecast - by Stage
- 8.2.1. Pre-clinical
- 8.2.2. Clinical
- 8.2.3. Commercial
- 8.3. Market Analysis, Insights and Forecast - by Indication
- 8.3.1. Oncology
- 8.3.2. Cardiovascular Diseases
- 8.3.3. Infectious Diseases
- 8.3.4. Genetic Diseases
- 8.3.5. Neurological Diseases
- 8.3.6. Others Indications
- 8.1. Market Analysis, Insights and Forecast - by Product
- 9. Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Product
- 9.1.1. Cell Therapy
- 9.1.1.1. Stem-cell Based
- 9.1.1.2. Non Stem-cell Based
- 9.1.1.3. Other Therapies
- 9.1.2. Gene Therapy
- 9.1.2.1. Viral Vectors
- 9.1.2.2. Non-viral Vectors
- 9.1.1. Cell Therapy
- 9.2. Market Analysis, Insights and Forecast - by Stage
- 9.2.1. Pre-clinical
- 9.2.2. Clinical
- 9.2.3. Commercial
- 9.3. Market Analysis, Insights and Forecast - by Indication
- 9.3.1. Oncology
- 9.3.2. Cardiovascular Diseases
- 9.3.3. Infectious Diseases
- 9.3.4. Genetic Diseases
- 9.3.5. Neurological Diseases
- 9.3.6. Others Indications
- 9.1. Market Analysis, Insights and Forecast - by Product
- 10. South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Product
- 10.1.1. Cell Therapy
- 10.1.1.1. Stem-cell Based
- 10.1.1.2. Non Stem-cell Based
- 10.1.1.3. Other Therapies
- 10.1.2. Gene Therapy
- 10.1.2.1. Viral Vectors
- 10.1.2.2. Non-viral Vectors
- 10.1.1. Cell Therapy
- 10.2. Market Analysis, Insights and Forecast - by Stage
- 10.2.1. Pre-clinical
- 10.2.2. Clinical
- 10.2.3. Commercial
- 10.3. Market Analysis, Insights and Forecast - by Indication
- 10.3.1. Oncology
- 10.3.2. Cardiovascular Diseases
- 10.3.3. Infectious Diseases
- 10.3.4. Genetic Diseases
- 10.3.5. Neurological Diseases
- 10.3.6. Others Indications
- 10.1. Market Analysis, Insights and Forecast - by Product
- 11. North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 11.1.1 United States
- 11.1.2 Canada
- 11.1.3 Mexico
- 12. Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 12.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 12.1.1 United Kingdom
- 12.1.2 Germany
- 12.1.3 France
- 12.1.4 Spain
- 12.1.5 Italy
- 12.1.6 Rest of Europe
- 13. Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 13.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 13.1.1 India
- 13.1.2 Japan
- 13.1.3 China
- 13.1.4 Australia
- 13.1.5 South Korea
- 13.1.6 Rest of Asia Pacific
- 14. South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 14.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 14.1.1 Brazil
- 14.1.2 Argentina
- 14.1.3 Rest of South America
- 15. Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 15.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 15.1.1 GCC
- 15.1.2 South Africa
- 15.1.3 Rest of the Middle East and Africa
- 16. Competitive Analysis
- 16.1. Global Market Share Analysis 2024
- 16.2. Company Profiles
- 16.2.1 The Discovery Labs
- 16.2.1.1. Overview
- 16.2.1.2. Products
- 16.2.1.3. SWOT Analysis
- 16.2.1.4. Recent Developments
- 16.2.1.5. Financials (Based on Availability)
- 16.2.2 Patheon Inc
- 16.2.2.1. Overview
- 16.2.2.2. Products
- 16.2.2.3. SWOT Analysis
- 16.2.2.4. Recent Developments
- 16.2.2.5. Financials (Based on Availability)
- 16.2.3 Wuxi Advanced Therapies
- 16.2.3.1. Overview
- 16.2.3.2. Products
- 16.2.3.3. SWOT Analysis
- 16.2.3.4. Recent Developments
- 16.2.3.5. Financials (Based on Availability)
- 16.2.4 Lonza Group
- 16.2.4.1. Overview
- 16.2.4.2. Products
- 16.2.4.3. SWOT Analysis
- 16.2.4.4. Recent Developments
- 16.2.4.5. Financials (Based on Availability)
- 16.2.5 Almac Group
- 16.2.5.1. Overview
- 16.2.5.2. Products
- 16.2.5.3. SWOT Analysis
- 16.2.5.4. Recent Developments
- 16.2.5.5. Financials (Based on Availability)
- 16.2.6 Charles River Laboratories International Inc
- 16.2.6.1. Overview
- 16.2.6.2. Products
- 16.2.6.3. SWOT Analysis
- 16.2.6.4. Recent Developments
- 16.2.6.5. Financials (Based on Availability)
- 16.2.7 Pfizer CentreOne
- 16.2.7.1. Overview
- 16.2.7.2. Products
- 16.2.7.3. SWOT Analysis
- 16.2.7.4. Recent Developments
- 16.2.7.5. Financials (Based on Availability)
- 16.2.8 PCI Pharma Services
- 16.2.8.1. Overview
- 16.2.8.2. Products
- 16.2.8.3. SWOT Analysis
- 16.2.8.4. Recent Developments
- 16.2.8.5. Financials (Based on Availability)
- 16.2.9 BIOCENTRIQ
- 16.2.9.1. Overview
- 16.2.9.2. Products
- 16.2.9.3. SWOT Analysis
- 16.2.9.4. Recent Developments
- 16.2.9.5. Financials (Based on Availability)
- 16.2.10 Catalent Inc
- 16.2.10.1. Overview
- 16.2.10.2. Products
- 16.2.10.3. SWOT Analysis
- 16.2.10.4. Recent Developments
- 16.2.10.5. Financials (Based on Availability)
- 16.2.11 FUJIFILM Diosynth Biotechnologies
- 16.2.11.1. Overview
- 16.2.11.2. Products
- 16.2.11.3. SWOT Analysis
- 16.2.11.4. Recent Developments
- 16.2.11.5. Financials (Based on Availability)
- 16.2.12 Recipharm AB
- 16.2.12.1. Overview
- 16.2.12.2. Products
- 16.2.12.3. SWOT Analysis
- 16.2.12.4. Recent Developments
- 16.2.12.5. Financials (Based on Availability)
- 16.2.1 The Discovery Labs
List of Figures
- Figure 1: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Breakdown (Million, %) by Region 2024 & 2032
- Figure 2: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 3: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 4: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 5: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 6: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 7: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 8: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 9: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 10: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 11: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 12: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Product 2024 & 2032
- Figure 13: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Product 2024 & 2032
- Figure 14: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Stage 2024 & 2032
- Figure 15: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Stage 2024 & 2032
- Figure 16: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Indication 2024 & 2032
- Figure 17: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Indication 2024 & 2032
- Figure 18: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 19: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 20: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Product 2024 & 2032
- Figure 21: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Product 2024 & 2032
- Figure 22: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Stage 2024 & 2032
- Figure 23: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Stage 2024 & 2032
- Figure 24: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Indication 2024 & 2032
- Figure 25: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Indication 2024 & 2032
- Figure 26: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 27: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 28: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Product 2024 & 2032
- Figure 29: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Product 2024 & 2032
- Figure 30: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Stage 2024 & 2032
- Figure 31: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Stage 2024 & 2032
- Figure 32: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Indication 2024 & 2032
- Figure 33: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Indication 2024 & 2032
- Figure 34: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 35: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 36: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Product 2024 & 2032
- Figure 37: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Product 2024 & 2032
- Figure 38: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Stage 2024 & 2032
- Figure 39: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Stage 2024 & 2032
- Figure 40: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Indication 2024 & 2032
- Figure 41: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Indication 2024 & 2032
- Figure 42: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 43: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 44: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Product 2024 & 2032
- Figure 45: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Product 2024 & 2032
- Figure 46: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Stage 2024 & 2032
- Figure 47: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Stage 2024 & 2032
- Figure 48: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Indication 2024 & 2032
- Figure 49: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Indication 2024 & 2032
- Figure 50: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 51: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 3: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 4: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 5: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Region 2019 & 2032
- Table 6: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 7: United States Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 8: Canada Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 9: Mexico Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 10: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 11: United Kingdom Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 12: Germany Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 13: France Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 14: Spain Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 15: Italy Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 16: Rest of Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 17: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 18: India Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 19: Japan Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 20: China Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 21: Australia Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 22: South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 23: Rest of Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 24: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 25: Brazil Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 26: Argentina Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 27: Rest of South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 28: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 29: GCC Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 30: South Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 31: Rest of the Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 32: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 33: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 34: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 35: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 36: United States Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 37: Canada Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 38: Mexico Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 39: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 40: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 41: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 42: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 43: United Kingdom Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 44: Germany Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 45: France Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 46: Spain Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 47: Italy Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 48: Rest of Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 49: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 50: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 51: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 52: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 53: India Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 54: Japan Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 55: China Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 56: Australia Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 57: South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 58: Rest of Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 59: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 60: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 61: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 62: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 63: GCC Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 64: South Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 65: Rest of the Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 66: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 67: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 68: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 69: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 70: Brazil Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 71: Argentina Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 72: Rest of South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Cell And Gene Therapy Contract Development And Manufacturing Organization Market?
The projected CAGR is approximately 16.73%.
2. Which companies are prominent players in the Cell And Gene Therapy Contract Development And Manufacturing Organization Market?
Key companies in the market include The Discovery Labs, Patheon Inc, Wuxi Advanced Therapies, Lonza Group, Almac Group, Charles River Laboratories International Inc, Pfizer CentreOne, PCI Pharma Services, BIOCENTRIQ, Catalent Inc, FUJIFILM Diosynth Biotechnologies, Recipharm AB.
3. What are the main segments of the Cell And Gene Therapy Contract Development And Manufacturing Organization Market?
The market segments include Product, Stage, Indication.
4. Can you provide details about the market size?
The market size is estimated to be USD 3.18 Million as of 2022.
5. What are some drivers contributing to market growth?
Rise In Preclinical and Clinical Activities Around Cell and Gene Therapies; Growing Burden of Genetic Diseases and Cancer; Increasing Research and Development Investment for Cell and Gene Therapy.
6. What are the notable trends driving market growth?
Neurological Disorders Segment is Expected to Hold a Significant Share Over the Forecast Period.
7. Are there any restraints impacting market growth?
Limitations in Analytical Methods for Large-scale AAV Biomanufacturing; Complex Manufacturing Process and Regulatory Challenges.
8. Can you provide examples of recent developments in the market?
March 2023: Porton Advanced Solutions Ltd. partnered with DanausGT Biotechnology Co., Ltd. as an end-to-end gene and cell therapy service provider. Porton Advanced will provide DanausGT with comprehensive solutions, including plasmids, viruses, and cell therapy products. By combining Porton Advanced's expertise with DanausGT's proprietary CRISPR/AAV technology, the collaboration accelerated the development of cutting-edge cell and gene therapy therapeutics.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Cell And Gene Therapy Contract Development And Manufacturing Organization Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Cell And Gene Therapy Contract Development And Manufacturing Organization Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Cell And Gene Therapy Contract Development And Manufacturing Organization Market?
To stay informed about further developments, trends, and reports in the Cell And Gene Therapy Contract Development And Manufacturing Organization Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database



Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations

Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence